103,858 Shares in BioNTech SE (NASDAQ:BNTX) Bought by abrdn plc

abrdn plc acquired a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 103,858 shares of the company's stock, valued at approximately $10,961,000.

Several other hedge funds have also modified their holdings of BNTX. Baillie Gifford & Co. raised its stake in shares of BioNTech by 15.5% in the third quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company's stock valued at $934,612,000 after acquiring an additional 1,152,541 shares in the last quarter. Clearbridge Investments LLC increased its holdings in BioNTech by 41.6% in the third quarter. Clearbridge Investments LLC now owns 484,126 shares of the company's stock valued at $52,595,000 after buying an additional 142,344 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in BioNTech by 43.1% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company's stock valued at $44,610,000 after buying an additional 127,951 shares during the last quarter. Bamco Inc. NY increased its holdings in BioNTech by 123.1% in the third quarter. Bamco Inc. NY now owns 158,911 shares of the company's stock valued at $17,264,000 after buying an additional 87,686 shares during the last quarter. Finally, Flossbach Von Storch AG increased its holdings in BioNTech by 2.1% in the third quarter. Flossbach Von Storch AG now owns 3,513,215 shares of the company's stock valued at $381,676,000 after buying an additional 71,468 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $0.50 during midday trading on Friday, reaching $87.21. 355,703 shares of the company were exchanged, compared to its average volume of 664,259. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. BioNTech SE has a 1 year low of $85.21 and a 1 year high of $125.83. The stock has a fifty day simple moving average of $90.77 and a 200 day simple moving average of $96.53. The stock has a market cap of $20.73 billion, a P/E ratio of 21.17 and a beta of 0.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $2.04 billion. On average, research analysts forecast that BioNTech SE will post -1.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $107.00 target price on shares of BioNTech in a report on Wednesday, April 17th. JPMorgan Chase & Co. dropped their target price on BioNTech from $99.00 to $90.00 and set an "underweight" rating on the stock in a report on Friday, March 22nd. Oppenheimer began coverage on BioNTech in a report on Friday, January 5th. They issued a "market perform" rating on the stock. The Goldman Sachs Group dropped their price objective on BioNTech from $113.00 to $100.00 and set a "neutral" rating on the stock in a report on Wednesday, February 28th. Finally, BMO Capital Markets dropped their price objective on BioNTech from $127.00 to $123.00 and set an "outperform" rating on the stock in a report on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of "Hold" and a consensus price target of $120.40.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.